OTCMKTS:CVSI - CV Sciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.68
  • Forecasted Upside: 67.90 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.40
▼ -0.03 (-6.94%)
1 month | 3 months | 12 months
Get New CV Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CVSI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CVSI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.68
▲ +67.90% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for CV Sciences in the last 3 months. The average price target is $0.68, with a high forecast of $0.95 and a low forecast of $0.50. The average price target represents a 67.90% upside from the last price of $0.40.

Hold

The current consensus among 4 contributing investment analysts is to hold stock in CV Sciences. This rating has held steady since April 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/25/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$0.50
i
3/19/2021Roth CapitalLower Price TargetNeutral$0.75 ➝ $0.60
i
3/19/2021Piper SandlerDowngradeOverweight ➝ Neutral$0.50
i
1/29/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$1.35 ➝ $0.65
i
Rating by P. Zuanic at Cantor Fitzgerald
12/8/2020Cantor FitzgeraldReiterated RatingOverweight
i
Rating by P. Zuanic at Cantor Fitzgerald
8/7/2020Northland SecuritiesReiterated RatingBuy$0.95
i
6/12/2020CowenInitiated CoverageMarket Perform$0.75
i
4/7/2020Cantor FitzgeraldBoost Price TargetOverweight$0.80 ➝ $1.70
i
3/17/2020Roth CapitalDowngradeBuy ➝ Neutral
i
Rating by Scott Fortune at Roth Capital
3/9/2020Cantor FitzgeraldBoost Price TargetOverweight$1.60 ➝ $4.20
i
11/7/2019Cantor FitzgeraldInitiated CoverageOverweight
i
8/12/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$5.00
i
5/16/2019Roth CapitalInitiated CoverageBuy ➝ Buy$9.00
i
Rating by S. Fortune at Roth Capital
5/9/2019Northland SecuritiesReiterated RatingBuy
i
4/11/2019Northland SecuritiesReiterated RatingBuy$8.00
i
3/13/2019Northland SecuritiesReiterated RatingBuy$8.00
i
1/24/2019Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$8.00
i
(Data available from 6/16/2016 forward)
CV Sciences logo
CV Sciences, Inc. operates as a life science company in the United States. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD name in various market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchandise retailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
Read More

Today's Range

Now: $0.40
$0.40
$0.43

50 Day Range

MA: $0.41
$0.36
$0.50

52 Week Range

Now: $0.40
$0.35
$1.12

Volume

230,183 shs

Average Volume

954,438 shs

Market Capitalization

$43.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.29

Frequently Asked Questions

What sell-side analysts currently cover shares of CV Sciences?

The following Wall Street sell-side analysts have issued stock ratings on CV Sciences in the last year: Cantor Fitzgerald, Northland Securities, Piper Sandler, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for CVSI.

What is the current price target for CV Sciences?

4 Wall Street analysts have set twelve-month price targets for CV Sciences in the last year. Their average twelve-month price target is $0.68, suggesting a possible upside of 67.9%. Northland Securities has the highest price target set, predicting CVSI will reach $0.95 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $0.50 for CV Sciences in the next year.
View the latest price targets for CVSI.

What is the current consensus analyst rating for CV Sciences?

CV Sciences currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CVSI, but not buy more shares or sell existing shares.
View the latest ratings for CVSI.

What other companies compete with CV Sciences?

How do I contact CV Sciences' investor relations team?

CV Sciences' physical mailing address is 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121. The company's listed phone number is 866-290-2157 and its investor relations email address is [email protected] The official website for CV Sciences is www.cvsciences.com.